SCHEMBL2448307

SCHEMBL2448307

COc1cccc(/C=N\O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 1/20 0.72
TAAR1 Q96RJ0 1/20 0.63
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
RECQL P46063 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
RELA Q04206 1/20 0.55
G6PC1 P35575 1/20 0.53
NFE2L2 Q16236 2/20 0.51
PTGS2 P35354 1/20 0.50
CYP19A1 P11511 1/20 0.50
NQO2 P16083 1/20 0.50
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KDM4E B2RXH2 1/20 0.49
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2121152 1.00 CHRM5 (0.72) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL2121150 1.00 CHRM5 (0.72) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL2804211 0.88 CHRM5 (0.57) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL13125667 0.88 CHRM5 (0.57) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL2804212 0.88 CHRM5 (0.57) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL1654602 0.84 CHRM5 (1.00) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL7107239 0.82 CHRM5 (0.75) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL7107242 0.82 CHRM5 (0.75) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL6261044 0.81 CHRM5 (0.72) CHRM5TAAR1CYP1A2CYP3A4RECQL
SCHEMBL14950238 0.81 CHRM5 (0.72) CHRM5TAAR1CYP1A2CYP3A4RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366704-B1 Inhibitors of serine proteases VERTEX PHARMA (US) 2013-10-23 EP disclosed
EP-2631238-A1 Spirocyclic inhibitors of serine proteases for the treatment of hcv infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-28 EP disclosed
EP-1917269-B1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMA (US) 2011-10-26 EP disclosed
EP-2366704-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-21 EP disclosed
EP-2364984-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-14 EP disclosed
US-7612069-B2 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-03 US disclosed
US-7612069-B2 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-03 US disclosed
US-7273882-B2 Aminoacetamide acyl guanidines as β-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 US disclosed
US-7273882-B2 Aminoacetamide acyl guanidines as β-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 US disclosed
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-01-18 US disclosed
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-01-18 US disclosed
WO-2007002214-A2 ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 WO disclosed
WO-2007002220-A2 AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 WO disclosed
US-4283403-A Substituted isoxazolines for control of plant phytopathogens ELI LILLY AND COMPANY (US) 1981-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BACE1, APP, BACE2 CHRM5 968/4885TAAR1 2032/4885CYP1A2 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.